Stock of the Day

November 8, 2022

DexCom (DXCM)

$90.93
-$0.14 (-0.1%)
Market Cap: $34.33B

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Bull Case

Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • The current stock price is around $77, which is significantly below its twelve-month high of $92.56, indicating potential for price appreciation.
  • DexCom, Inc. reported a strong quarterly revenue of $1.31 billion, exceeding analyst expectations, which reflects robust demand for its continuous glucose monitoring systems.
  • The company has demonstrated impressive year-over-year revenue growth of 13.1%, suggesting a positive trend in its business performance.
  • With a net margin of over 20%, DexCom, Inc. shows strong profitability, which can lead to higher returns for investors.
  • The firm has a high return on equity of 35.94%, indicating effective management and the ability to generate profits from shareholders' equity.

DexCom Bear Case

Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • The stock has a relatively high P/E ratio of 36.50, which may suggest that it is overvalued compared to its earnings, potentially limiting future price growth.
  • Despite strong performance, the stock's beta of 1.41 indicates higher volatility compared to the market, which could lead to greater risk for investors.
  • Analysts have mixed ratings, with one sell rating among the majority of buy ratings, indicating some uncertainty in the stock's future performance.
  • The company has a debt-to-equity ratio of 0.47, which, while manageable, suggests that it is not entirely free from debt obligations that could impact financial flexibility.
  • Recent analyst reports have shown some downgrades in ratings, which may reflect concerns about future growth prospects in a competitive market.
← Previous Stock of the DayNext Stock of the Day →

Recent News